Irreversible extreme freezing of gait after dopamine agonist withdrawal [PDF]
Clinical Case Reports (discontinued), 2021 Dopamine agonist withdrawal can cause freezing of gait in PD patients.
Mehri Salari +2 more
exaly +3 more sources
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas [PDF]
Frontiers in Endocrinology, 2019 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions.
Xiaoshuang Liu +6 more
openaire +3 more sources
Dopamine Agonists and Pathologic Behaviors [PDF]
Parkinson's Disease, 2012 The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive ...
Brendan J. Kelley +2 more
openaire +3 more sources
Dopamine Agonists for Pituitary Adenomas [PDF]
Frontiers in Endocrinology, 2018 Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor subtypes express D2R to varying degrees, leading to an extensive body of research into potential ...
Odelia Cooper, Yona Greenman
openaire +3 more sources
Dopamine agonist monotherapy utilization in patients with Parkinson's disease. [PDF]
Clin Park Relat Disord, 2023 Frazer M, Arcona S, Le L, Sasane R.
europepmc +1 more source
TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA. [PDF]
Acta Endocrinol (Buchar), 2023 Giraldi EA +4 more
europepmc +1 more source
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. [PDF]
Cell Rep Med, 2023 Abe Y +18 more
europepmc +1 more source
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia. [PDF]
Mov Disord, 2023 Espa E +4 more
europepmc +1 more source
Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. [PDF]
Front Endocrinol (Lausanne), 2023 Wang L, Wang X, Gong F, Pan H, Zhu H.
europepmc +1 more source